SFRP1 and hepatocellular carcinoma: In line with this observation, other Wnt antagonists (e.g., sFRP1 and WIF1) inhibit tumor angiogenesis in hepatocellular carcinoma by preventing both EC proliferation/migration and endothelial precursor cell differentiation [38].